International Journal of Gastrointestinal Intervention

Table. 1. Table 1

Clinical Trials of Systemic Treatments for Patients with Intermediate or Advanced Hepatocellular Carcinoma

Drug	Mechanism	Combination	Trial identifier	Phase
Sorafenib	A protein kinase inhibitor	Sorafenib + DEB-TACE vs DEB-TACE alone	NCT00855218	2
		Sorafenib + DEB-TACE vs DEB-TACE alone	ISRCTN93375053	3
		Sorafenib + TACE vs TACE alone	NCT01217034	2
		Sorafenib + HAIC	NCT03722498	2
Brivanib	VEGFR2 inhibitor	Brivanib after TACE vs TACE alone	NCT00908752	3
Orantinib	VEGFR inhibitor	Orantinib + TACE vs TACE alone	NCT01465464	3
Camrelizumab + Apatinib	Anti-PD-1 immune checkpoint inhibitor + Tyrosine kinase inhibitor	Camrelizumab + Apatinib + TACE	NCT04479527	2
Tremelimumab	A monoclonal antibody against CTLA-4	Tremelimumab + RFA or TACE	NCT01853618	1/2
Durvalumab + Tremelimumab	Anti-PD-1 antibody + A monoclonal antibody against CTLA-4	Durvalumab + Tremelimumab after DEB-TACE	NCT01853618	1/2
Durvalumab + Bevacizumab	Anti-PD-1 antibody + Anti-VEGF antibody	Durvalumab + Bevacizumab + DEB-TACE	NCT03937830	2
Nivolumab	Anti-PD-1 antibody	Nivolumab + DEB-TACE	NCT03143270	1
		Nivolumab + TACE	NCT03572582	2
Pembrolizumab	Anti-PD-1 antibody	Pembrolizumab after TACE	NCT03397654	1/2
Immune killer cells	Immune killer cells	Immune killer cells + TACE vs TACE alone	NCT03592706	2/3

DEB-TACE, drug-eluting beads using transarterial chemoembolization; HAIC, hepatic arterial infusion chemotherapy; VEGFR, vascular endothelial growth factor receptor; anti-PD-1, anti-programmed cell death protein-1; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; RFA, radiofrequency ablation; anti-VEGF, anti-vascular endothelial growth factor.

Int J Gastrointest Interv 2021;10:183~188 https://doi.org/10.18528/ijgii210046